Baird’s Novartis NVS Stock Holding History

Baird’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	$7.24M	Sell	81,899 -5,965	-7%	-$529K	0.07%	263
2014 Q4	$7.29M	Sell	87,864 -6,697	-7%	-$555K	0.08%	262
2014 Q3	$7.98M	Buy	94,561 +14,958	+19%	+$1.21M	0.11%	187
2014 Q2	$6.46M	Sell	79,603 -30	-0%	-$2.36K	0.09%	211
2014 Q1	$6.07M	Sell	79,633 -461,689	-85%	-$33.6M	0.09%	223
2013 Q4	$39M	Sell	541,322 -9,724	-2%	-$676K	0.67%	24
2013 Q3	$37.9M	Sell	551,046 -15,077	-3%	-$998K	0.71%	21
2013 Q2	$35.9M	Buy	+566,123	New	+$36.8M	0.71%	23

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Baird's NVS Position: Q1 2015 in Review

Baird reduced its Novartis (NVS) stake by 6.8% in Q1 2015, selling an estimated $529K and leaving 81,899 shares worth $7.24M. The position accounts for 0.07% of the portfolio, ranked #263.

Baird first reported a position in NVS in Q2 2013 and has held it in 8 quarters since. The position peaked at $39M in Q4 2013. 940 funds tracked by Wall St. Rank hold NVS as of Q1 2015.

Baird held 81,899 shares of Novartis worth $7.24M as of Q1 2015.
Baird sold 5,965 Novartis shares in Q1 2015, an estimated $529K.
Novartis made up 0.07% of Baird's portfolio in Q1 2015, its #263 holding.
Baird first reported a position in Novartis in Q2 2013 and has held it in 8 quarters since.
Baird's Novartis position peaked at $39M in Q4 2013.
940 funds tracked by Wall St. Rank held Novartis as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.